Corrigendum to “Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study” [Drug Alcohol Depend. 162 (2016) 245-250] (S0376871616001204) (10.1016/j.drugalcdep.2016.02.036));Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study

Drug and Alcohol Dependence

Volumn 162, Issue , 2016, Pages 245-250

  Worley, Matthew J ^a   Heinzerling, Keith G ^a   Roche, Daniel J O ^a   Shoptaw, Steve ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ibudilast; Methamphetamine; Neuroinflammation; Pharmacotherapy; Subjective reward

Indexed keywords

IBUDILAST; METHAMPHETAMINE; PLACEBO; SODIUM CHLORIDE; PYRIDINE DERIVATIVE; VASODILATOR AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE; AMPHETAMINE-RELATED DISORDERS; ANTAGONISTS AND INHIBITORS; DRUG SELF ADMINISTRATION; MIDDLE AGED; PSYCHOLOGY; REWARD;

ADULT; AMPHETAMINE-RELATED DISORDERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INPATIENTS; MALE; METHAMPHETAMINE; MIDDLE AGED; PYRIDINES; REWARD; SELF ADMINISTRATION; VASODILATOR AGENTS;

EID: 84961145775     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2018.06.002     Document Type: Erratum

References (36)

1. Beardsley P.M., Hauser K.F. Glial modulators as potential treatments of psychostimulant abuse. Adv. Pharmacol. 2014, 69:1-69.
2. Beardsley P.M., Shelton K.L., Hendrick E., Johnson K.W. The glial cell modulator and phosphodiesterase inhibitor AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse. Eur. J. Pharmacol. 2010, 637:102-108.
3. Bell R.L., Lopez M.F., Cui C., Egli M., Johnson K.W., Franklin K.M., Becker H.C. Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addict. Biol. 2015, 20:38-42.
4. Bland S.T., Hutchinson M.R., Maier S.F., Watkins L.R., Johnson K.W. The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain. Behav. Immun. 2009, 23:492-497.
5. Brensilver M., Heinzerling K.G., Shoptaw S. Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug Alcohol Rev. 2013, 32:449-460.
6. Cacciola J.S., Alterman A.I., McLellan A.T., Lin Y.T., Lynch K.G. Initial evidence for the reliability and validity of a lite version of the addiction severity index. Drug Alcohol Depend. 2007, 87:297-302.
7. Cho Y., Crichlow G.V., Vermeire J.J., Leng L., Du X., Hodsdon M.E., Bucala R., Cappello M., Gross M., Gaeta F., Johnson K., Lolis E.J. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11313-11318.
8. Coller J.K., Hutchinson M.R. Implications of central immune signaling caused by drugs of abuse: mechanisms: mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacol. Ther. 2012, 134:219-245.
9. Comer S.D., Ashworth J.B., Foltin R.W., Johanson C.E., Zacny J.P., Walsh S.L. The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend. 2008, 96:1-15.
10. Darke S., Kaye S., McKetin R., Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008, 27:253-262.
11. De La Garza R., 2nd Zorick T., London E.D., Newton T.F. Evaluation of modafinil effects on cardiovascular subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug Alcohol Depend. 2010, 106:173-180.
12. DeYoung, D., Heinzerling, K.G., Swanson, A., Tsuang, J., Furst, B., Yi, Y., Wu, Y.N., Shoptaw, S., under review. Cardiovascular safety of ibudilast treatment with intravenous methamphetamine administration.
13. Dean A.C., Groman S.M., Morales A.M., London E.D. An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology 2013, 38:259-274.
14. Freeman P., Walker B.C., Harris D.R., Garofalo R., Willard N., Ellen J.M., Adolescent Trials Network for, H.I.V.A.I.b.T Methamphetamine use and risk for HIV among young men who have sex with men in 8 US cities. Arch. Pediatr. Adolesc. Med. 2011, 165:736-740.
15. Gibson L.C., Hastings S.F., McPhee I., Clayton R.A., Darroch C.E., Mackenzie A., Mackenzie F.L., Nagasawa M., Stevens P.A., Mackenzie S.J. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur. J. Pharmacol. 2006, 538:39-42.
16. Hoyle R.H., Gottfredson N.C. Sample size considerations in prevention research applications of multilevel modeling and structural equation modeling. Prev. Sci. 2014, 16:987-996.
17. Hutchinson M.R., Watkins L.R. Why is neuroimmunopharmacology crucial for the future of addiction research?. Neuropharmacology 2014, 76(Pt. B):218-227.
18. LaVoie M.J., Card J.P., Hastings T.G. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp. Neurol. 2004, 187:47-57.
19. Ling W., Rawson R., Shoptaw S., Ling W. Management of methamphetamine abuse and dependence. Curr. Psychiatry Rep. 2006, 8:345-354.
20. Loftis J.M., Choi D., Hoffman W., Huckans M.S. Methamphetamine causes persistent immune dysregulation: a cross-species translational report. Neurotox. Res. 2011, 20:59-68.
21. Mizuno T., Kurotani T., Komatsu Y., Kawanokuchi J., Kato H., Mitsuma N., Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 2004, 46:404-411.
22. Morean M.E., de Wit H., King A.C., Sofuoglu M., Rueger S.Y., O'Malley S.S. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl.) 2013, 227:177-192.
23. Narita M., Miyatake M., Narita M., Shibasaki M., Shindo K., Nakamura A., Kuzumaki N., Nagumo Y., Suzuki T. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 2006, 31:2476-2488.
24. Narita M., Suzuki M., Kuzumaki N., Miyatake M., Suzuki T. Implication of activated astrocytes in the development of drug dependence: differences between methamphetamine and morphine. Ann. N. Y. Acad. Sci 2008, 1141:96-104.
25. Newton T.F., Roache J.D., De La Garza R., Fong T., Wallace C.L., Li S.H., Elkashef A., Chiang N., Kahn R. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006, 31:1537-1544.
26. Niwa M., Nitta A., Yamada Y., Nakajima A., Saito K., Seishima M., Shen L., Noda Y., Furukawa S., Nabeshima T. An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization. Biol. Psychiatry 2007, 61:890-901.
27. Ostrow D.G., Plankey M.W., Cox C., Li X., Shoptaw S., Jacobson L.P., Stall R.C. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J. Acquir. Immune Defic. Syndr. 2009, 51:349-355.
28. Rush C.R., Stoops W.W., Lile J.A., Glaser P.E., Hays L.R. Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance. Psychopharmacology (Berl.) 2011, 214:665-674.
29. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., Iwata Y., Tsuchiya K.J., Suda S., Suzuki K., Kawai M., Takebayashi K., Yamamoto S., Matsuzaki H., Ueki T., Mori N., Gold M.S., Cadet J.L. Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 2008, 28:5756-5761.
30. Snider S.E., Hendrick E.S., Beardsley P.M. Glial cell modulators attenuate methamphetamine self-administration in the rat. Eur. J. Pharmacol. 2013, 701:124-130.
31. Spitzer R.L., Williams J., Gibbon M., First M.B. The Structured Clinical Interview for DSM-IV 1995, American Psychiatric Press, Washington, DC.
32. StataCorp, Stata: Release 13 2013, StataCorp LP, College Station, TX.
33. Suzumura A., Ito A., Yoshikawa M., Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 1999, 837:203-212.
34. Thomas D.M., Kuhn D.M. Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J. Neurochem. 2005, 92:790-797.
35. Vickers A.J., Altman D.G. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001, 323:1123-1124.
36. Vocci F.J., Appel N.M. Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction 2007, 102(Suppl. 1):96-106.